

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/690,199
				Filing Date	2003-10-21
				First Named Inventor	Astasturov, et al.
				Art Unit	1632
				Examiner Name	Wu Cheng Winston Shen
Sheet	1	of	12	Attorney Docket No: API-02-13-US	

U.S. PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	4,923,808	1990-05-08	Matteucci, et al.	Entire document
	A2	5,093,258	1992-03-03	Cohen, et al.	Entire document
	A3	5,141,742	1992-08-05	Brown, et al.	Entire document
	A4	5,342,774	1994-08-30	Boon, et al.	Entire document
	A5	5,405,940	1995-04-11	Boon, et al.	Entire document
	A6	5,462,871	1995-10-31	Boon-Fauler, et al.	Entire document
	A7	5,505,941	1996-04-09	Paoletti, E.	Entire document
	A8	5,554,724	1996-09-10	Melief, et al.	Entire document
	A9	5,585,461	1996-12-17	Townsend, et al.	Entire document
	A10	5,591,430	1997-01-07	Chaux, et al.	Entire document
	A11	5,679,647	1997-10-21	Carson, et al.	Entire document
	A12	5,686,068	1997-11-11	Melief, et al.	Entire document
	A13	5,695,994	1997-12-09	Boon-Fauler, et al.	Entire document
	A14	5,698,530	1997-12-16	Schlom, J.	Entire document
	A15	5,804,566	1998-09-08	Carson, et al.	Entire document
	A16	5,830,877	1998-11-03	Carson, et al.	Entire document
	A17	5,831,016	1998-11-03	Wang, et al.	Entire document
	A18	5,840,839	1998-11-24	Wang, et al.	Entire document
	A19	5,844,075	1998-12-01	Kawakami, et al.	Entire document
	A20	5,851,523	1998-12-22	Townsend, et al.	Entire document
	A21	5,871,727	1996-12-06	Curiel, D.	Entire document
	A22	5,874,560	1999-02-23	Kawakami, et al.	Entire document
	A23	5,942,235	1999-08-24	Paoletti, et al.	Entire document
	A24	5,965,535	1999-10-12	Chaux, et al.	Entire document
	A25	5,972,597	1999-10-26	Paoletti, et al.	Entire document
	A26	5,985,847	1999-11-16	Carson, et al.	Entire document
	A27	6,001,349	1999-12-14	Paricali, et al.	Entire document
	A28	6,025,474	2000-02-15	Van Den Eynde, et al.	Entire document
	A29	6,037,135	2000-03-14	Kubo, et al.	Entire document
	A30	6,045,802	2000-04-04	Schlom, et al.	Entire document
	A31	6,083,703	2000-07-04	Wang, et al.	Entire document
	A32	6,087,110	2000-07-11	Wang, et al.	Entire document
	A33	6,127,116	2000-10-03	Rice, et al.	Entire document
	A34	6,132,980	2000-10-17	Wang, et al.	Entire document

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/690,199
				Filing Date	2003-10-21
				First Named Inventor	Astasturov, et al.
				Art Unit	1632
				Examiner Name	Wu Cheng Winston Shen
Sheet	2	of	12	Attorney Docket No: API-02-13-US	

U.S. PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A35	6,228,621	2001-05-08	Williams, et al.	Entire document
	A36	6,245,333	2001-06-12	Coulie, et al.	Entire document
	A37	6,319,496	2001-11-20	Panicali, et al.	Entire document
	A38	6,340,462	2002-01-22	Paoletti, et al.	Entire document
	A39	6,407,063	2002-06-18	Luiten, et al.	Entire document
	A40	6,511,800	2003-01-28	Parks, et al.	Entire document
	A41	6,531,451	2003-03-11	Chaux, et al.	Entire document
	A42	6,548,068	2003-04-15	Schlom, et al.	Entire document
	A43	6,558,671	2003-05-06	Stingluff, et al.	Entire document
	A44	6,537,560	2003-03-25	Kawakami, et al.	Entire document
	A45	6,599,699	2003-07-29	Gaugler, et al.	Entire document
	A46	6,656,734B1	2003-12-02	Bischoff, et al.	Entire document
	A47	6,693,086	2004-02-17	Dow, et al.	Entire document
	A48	6,699,475	2003-05-06	Stingluff, et al.	Entire document
	A49	6,756,038	2004-06-29	Schlom, et al.	Entire document
	A50	6,780,407	2004-08-24	Paoletti, et al.	Entire document
	A51	6,710,172	2004-03-23	Chaux, et al.	Entire document
	A52	6,805,869	2004-10-19	Guo, Y.	Entire document
	A53	6,893,869	2005-05-17	Schlom, et al.	Entire document
	A54	6,951,917	2005-10-04	Topalian, et al.	Entire document
	A55	6,969,609	2005-11-29	Schlom, et al.	Entire document
	A56	7,211,432	2007-05-01	Schlom, et al.	Entire document
	A57	7,255,862	2007-08-14	Tartaglia, et al.	Entire document
	A58	7,232,887	2007-06-19	Kawakami, et al.	Entire document
	A59	7,364,729	2008-04-29	Kundig, et al.	Entire document
	A60	2001/0007659A1	2001-07-12	Wong-Smaal, et al.	Entire document
	A61	2002/0123471A1	2002-09-05	Uberla, K.	Entire document
	A62	2003/0022854A1	2003-01-30	Dow, et al.	Entire document
	A63	2003/0082150A1	2003-05-01	Boon-Fauler, et al.	Entire document
	A64	2003/0113919A1	2003-06-19	Emtage, et al.	Entire document
	A65	2004/003323A1	2004-02-19	Berinstein, et al.	Entire document
	A66	2004/0091995A1	2004-05-13	Schlom, et al.	Entire document
	A67	2004/0146485A1	2004-07-29	Belardelli, et al.	Entire document
	A68	2004/0156861A1	2004-08-12	Figdor, et al.	Entire document

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/690,199
				Filing Date	2003-10-21
				First Named Inventor	Astasturov, et al.
				Art Unit	1632
				Examiner Name	Wu Cheng Winston Shen
Sheet	3	of	12	Attorney Docket No: API-02-13-US	

U.S. PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A69	2005/0136066A1	2005-06-23	Guo, Y.	Entire document
	A70	09/693,755	N/A	Berinstein, et al.	Entire document

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	B1	EP 1074267A1	2001-02-07	Sumimoto Chemical Co. Ltd.	Entire document	
	B2	WO 87/04076A	1987-07-16	Texas A&M University	Entire document	
	B3	WO 91/11194A1	1991-08-08	Biogen, Inc.	Entire document	
	B4	WO 92/01796	1991-07-13	Smith Kline Beecham Biol.	Entire document	
	B5	WO 92/21376A1	1992-12-10	Medimmune, Inc.	Entire document	
	B6	WO 96/11279	1995-10-02	United States Government	Entire document	
	B7	WO 97/15597A1	1997-05-01	Centocor B.V.	Entire document	
	B8	WO 98/15636	1997-10-10	Onn, T.	Entire document	
	B9	WO 98/04728A1	1998-02-05	United States Government	Entire document	
	B10	WO 98/29556A1	1998-07-09	The Wistar Institute	Entire document	
	B11	WO 99/18992A1	1999-04-22	Tovery, M.	Entire document	
	B12	WO 99/19501	1998-10-14	Inst. Vaccine Dev.	Entire document	
	B13	WO 99/18992A	1999-04-22	Pharma Pacific Pty Ltd	Entire document	
	B14	WO 99/30742A1	1998-12-11	Nakamura, et al.	Entire document	
	B15	WO 99/40188A2	1999-08-12	Cabazon, et al.	Entire document	
	B16	WO 99/43839A1	1999-09-02	Trustees of the Univ. Penn.	Entire document	
	B17	WO 99/46992A1	1999-09-23	Kaplan, et al.	Entire document	
	B18	WO 99/46988	1998-03-20	Genzyme Corporation	Entire document	
	B19	WO 01/75117A2	2001-02-26	Biowindow Gene Dev. Co.	Entire document	
	B20	WO 01/75016A2	2000-03-22	Biowindow Gene Dev. Co.	Entire document	
	B21	WO 01/30382A1	2001-05-03	Aventis Pasteur Limited	Entire document	
	B22	WO 01/30847A1	2001-05-03	Aventis Pasteur Limited	Entire document	
	B23	WO 03/080800A2	2003-10-02	Aventis Pasteur, Inc.	Entire document	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/690,199
				Filing Date	2003-10-21
				First Named Inventor	Astasturov, et al.
				Art Unit	1632
				Examiner Name	Wu Cheng Winston Shen
Sheet	4	of	12	Attorney Docket No: API-02-13-US	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	AARTS, et al. Vector-based Vaccine/Cytokine Combination Therapy to Enhance Induction of Immune Responses to a Self-Antigen and Antitumor Activity. Cancer Res. 62: 5770-5777 (Oct. 15, 2002)	
	C2	ABRAMOVICH, et al. Low Dose Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Interleukin-2 (IL-2) Are Well Tolerated Following Autologous Stem Cell Transplant (ASCT) in Patients (pts) with Hematologic-Malignancies. 1999 ASCO Annual Meeting, Abstract 205 (1999)	
	C3	AHLERS, et al. Mechanisms of Cytokine Synergy Essential for Vaccine Protection Against Viral Challenge. Int. Immunol. 13(7): 897-908 (2000)	
	C4	ANTON, et al. Cytokines and Tumor Vaccination. Cancer Biotherapeutics and Radiopharmaceuticals. 11(5): 315-318 (1996)	
	C5	ARCH, et al. Hypopigmentation Associated with an Adenovirus-Mediated gp100/MART-1 Transduced Dendritic Cell Vaccine for Metastatic Melanoma. Arch. Dermatol. 138(6): 799-802 (2002)	
	C6	ASTSATUROV, et al. Amplification of Virus-Induced Antimelanoma T-Cell Reactivity by High-Dose Interferon-Alpha 2b; Implications for Cancer Vaccines. Clin. Cancer Res. 9(12): 4347-4355 (2003)	
	C7	BAKKER, et al. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int. J. Cancer 70, 302-309 (1997)	
	C8	BALCH, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19: 3635-3648 (2001)	
	C9	BELARDELLI, et al. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today, 17: 369-372 (1996)	
	C10	BERINSTEIN, et al. Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: A Review. J. Clin. Oncol. 20(8): 2197-2207 (2002)	
	C11	BOEL, et al. BAGE: A New Gene Encoding an Antigen Recognized on Human Melanomas by Cytolytic T Lymphocytes. Immunity, 2: 167-175 (1995)	
	C12	BOON, et al. Tumor Antigens Recognized by T Lymphocytes. Ann. Rev. Immunol. 12:337-365 (1994)	
	C13	BOSSIO, et al. Seven Days of Low-Dose Orally Administered Murine Type I Interferon Does Not Cause Priming <i>In Vivo</i> . J. Interferon & Cytokine Res. 21(7): 463-467 (2001)	
	C14	BRASSEUR, et al. Human Gene MAGE-1, Which Codes for a Tumor Antigen, is Expressed by Some Breast Tumors. Int. J. Cancer 52: 839-841 (1992)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/690,199
				Filing Date	2003-10-21
				First Named Inventor	Astasturov, et al.
				Art Unit	1632
				Examiner Name	Wu Cheng Winston Shen
Sheet	5	of	12	Attorney Docket No: API-02-13-US	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C15	BRASSEUR, et al. Expression of MAGE Genes in Primary and Metastatic Cutaneous Melanoma. Int. J. Cancer 63: 375-380 (1995)	
	C16	BUELER, et al. Induction of Antigen-Specific Tumor Immunity by Genetic and Cellular Vaccines against MAGE: Enhanced Tumor Protection by Coexpression of Granulocyte-Macrophage Colony-Stimulating Factor and B7-1. Mol. Medicine, 2(5): 545-555 (1996)	
	C17	CHAMBERLAIN, et al. Costimulation Enhances the Active Immunotherapy Effect of Anticancer Vaccines. Cancer Res. 56: 2832-2836 (1996)	
	C18	CHAUX, et al. Five MAGE-A1 Epitopes Recognized by Cytolytic T Lymphocytes Obtained by In Vitro Stimulation with Dendritic Cells Transduced with MAGE-A1. J Immunol. 163: 2928-2936 (1999)	
	C19	CHEN, et al. Recombinant Interferon Alpha can Induce Rearrangement of T-Cell Antigen Receptor Alpha-Chain Genes and Maturation to Cytotoxicity in T-Lymphocyte Clones In Vitro. PNAS U.S.A. 83: 4887-4889 (1986)	
	C20	CHO, et al. IFN- $\alpha\beta$ Promote Priming of Antigen-Specific CD8+ and CD4+ T Lymphocytes by Immunostimulatory DNA-Based Vaccines. J. Immunol. 168: 4907-4913 (2002)	
	C21	CHOMEZ, et al. The SMAGE Gene Family is Expressed in Post-Meiotic Spermatids During Mouse Germ Cell Differentiation. Immunogenetics 43: 97-100 (1996)	
	C22	COX, et al. Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines. Science, vol. 264: 716-719 (1994)	
	C23	COULIE, et al. A Mutated Intron Sequence Codes for an Antigenic Peptide Recognized by Cytotoxic T Lymphocytes on a Human Melanoma. PNAS USA, 92: 7976-7980 (1995)	
	C24	DE PLAEN, et al. Structure, Chromosomal Localization, and Expression of 12 Genes of the MAGE Family. Immunogenetics 40: 360-369 (1994)	
	C25	DE SMET, et al. Sequence and Expression Pattern of the Human MAGE2 Gene. Immunogenetics 39:121-129 (1994)	
	C26	DISIS, et al. Granulocyte-Macrophage Colony-Stimulating Factor: An Effective Adjuvant for Protein and Peptide-Based Vaccines. Blood, 88(1): 202-210 (1996)	
	C27	DUBENSKY, et al. Delivery Systems for Gene-Based Vaccines. Mol. Med. 6(9): 723-732 (2000)	
	C28	ELLEM, et al. The labyrinthine ways of cancer immunotherapy--T cell, tumor cell encounter: "how do I lose thee? Let me count the ways". Adv. Cancer Res. 75:203-49; 203-249 (1998)	
	C29	EURA, et al. Expression of the MAGE Gene Family in Human Squamous Cell Carcinomas. Int. J. Cancer 64: 304-308 (1995)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/690,199
				Filing Date	2003-10-21
				First Named Inventor	Astasturov, et al.
				Art Unit	1632
				Examiner Name	Wu Cheng Winston Shen
Sheet	6	of	12	Attorney Docket No: API-02-13-US	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C30	FUJIE, et al. A MAGE-1-Encoded HLA-A24-Binding Synthetic Peptide Induces Specific Anti-Tumor Cytotoxic T Lymphocytes. <i>Int. J. Cancer</i> 80: 169-172 (1999)	
	C31	GAUGLER, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. <i>J. Exp. Med.</i> 179: 921-930 (1994)	
	C32	GRAMAGLIA, et al. OX-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses. <i>J. Immunol.</i> 161: 6510-6517 (1998)	
	C33	GROB, et al. Interferon as an adjuvant for Hepatitis B Vaccination in Non- and Low-Responder Populations. <i>Eur. J. Clin. Microb.</i> 3(3): 195-198 (1984)	
	C34	GURUNATHAN, et al. CD40 Ligand/Trimer DNA Enhances Both Humoral and Cellular Immune Responses and Induces Protective Immunity to Infectious and Tumor Immunity. <i>J. Immunol.</i> 161: 4563-4571 (1998)	
	C35	HALUSKA, et al. Immunologic Gene Therapy: A Phase I/II Trial Utilizing Autologous Dendritic Cells Transduced with gp100 and Melan A/MART-1-Encoding Adenoviruses in Advanced Melanoma. <i>Blood</i> , 98(1): 694a-695a, Abstract 2903 (Nov. 16, 2001)	
	C36	HEINTEGES, et al. Combination Therapy of Active HBSAG Vaccination and Interferon-Alpha in Interferon-Alpha Nonresponders with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 4(46): 901-906 (2001)	
	C37	HERMAN, et al. A Peptide Encoded by the Human MAGE3 Gene and Presented by LA-B44 Induces Cytolytic T Lymphocytes That Recognize MAGE3. <i>Immunogenetics</i> 43: 377-383 (1996)	
	C38	HERMONAT, et al. Use of Adeno-Associated Virus as a Mammalian DNA Cloning Vector: Transduction of Neomycin Resistance Into Mammalian Tissue Culture Cells. <i>PSNA USA</i> , 81: 6466-6470 (1984)	
	C39	HERZ, et al. Adenovirus-Mediated Transfer of Low Density Lipoprotein Receptor Gene Acutely Accelerates Cholesterol Clearance in Normal Mice. <i>PNAS USA</i> , 90: 2812-2816 (1993)	
	C40	HODGE, et al. Admixture of Recombinant Vaccinia Virus Containing the Gene for the Costimulatory Molecule B7 and a Recombinant Vaccinia Virus Containing a Tumor-associated Antigen Gene Results in Enhanced Specific T-Cell Responses and Antitumor Immunity. <i>Cancer Res.</i> 55: 3598-3603 (1995)	
	C41	HODGE, et al. Diversified Prime and Boost Protocols Using Recombinant Vaccine Virus and Recombinant Non-Replicating Avian Pox Virus to Enhance T-Cell Immunity and Antitumor Responses. <i>Vaccine</i> , vol. 15, issue 6/7, pp. 759-768 (1997)	
	C42	HODGE, et al. A Triad of Costimulatory Molecules Synergize to Amplify T-Cell Activation. <i>Cancer Res.</i> 59: 5800-5807 (1999)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/690,199
				Filing Date	2003-10-21
				First Named Inventor	Astasturov, et al.
				Art Unit	1632
				Examiner Name	Wu Cheng Winston Shen
Sheet	7	of	12	Attorney Docket No: API-02-13-US	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C43	HORIG, et al. Phase I Clinical Trial of Recombinant Canarypox (ALVAC) Vaccine Expressing Human Carcinoembryonic Antigen and B7.1 Costimulatory Molecule. Cancer Immunol. Immunother. 49: 504-514 (2000)	
	C44	HU, et al. Enhancement of T Lymphocyte Precursor Frequency in Melanoma Patients Following Immunization with the MAGE-1 Peptide Loaded Antigen Presenting Cell-Based Vaccine. Cancer Res. 56: 2479-2483 (1996)	
	C45	HURPIN, et al. The Mode of Presentation and Route of Administration Are Critical for the Induction of Immune Responses to p53 and Antitumor Immunity. Vaccine, vol. 16, no. 2/3, pp. 208-215 (1998)	
	C46	IL2 Therapy : Low Dose Daily vs. High Dose Intermittent Regimens. Author Unknown. (2001)	
	C47	INOUE, et al. Human Esophageal Carcinomas Frequently Express the Tumor-Rejection Antigens of MAGE Genes. Int. J. Cancer 63: 523-526 (1995)	
	C48	IRVINE, et al. Recombinant Virus Vaccination Against "Self" Antigens Using Anchor-Fixed Immunogens. Cancer Res., vol. 59: 2536-2540 (1999)	
	C49	KARAKINAS, et al. Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus. J. Immunol. 171: 4989-4904 (2003)	
	C50	KAWAKAMI, et al. Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with in vivo Tumor Rejection. Proc. Natl. Acad. Sci. USA, vol. 91, pp. 6458-6462 (1994)	
	C51	KAWAKAMI, et al. Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating Lymphocytes. J. Exp. Med. 180: 347-352 (1994)	
	C52	KAWASHIMA, et al. The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors. Human Immunol. 59: 1-14 (1998)	
	C53	KIRKWOOD, et al. Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma : The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14(1): 7-17 (1996)	
	C54	KIRKWOOD, et al. Systemic Adjuvant Treatment of High-Risk Melanoma: the Role of Interferon Alfa-2b and Other Immunotherapies. Eur. J. Cancer, 34: 12-17 (1998)	
	C55	KIRKWOOD, et al. High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190. J. Clin. Oncol. 18(12): 2444-2458 (2000)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/690,199
				Filing Date	2003-10-21
				First Named Inventor	Astasturov, et al.
				Art Unit	1632
				Examiner Name	Wu Cheng Winston Shen
Sheet	8	of	12	Attorney Docket No: API-02-13-US	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C56	KIRKWOOD, et al. High-Dose Interferon Alfa-2b Does Not Diminish Antibody Response to GM2 Vaccination in Patients With Resected Melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J. Clin. Oncol. 19: 1430-1436 (2001)	
	C57	KIRKWOOD, et al. High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801. J. Clin. Oncol. 19: 2370-2380 (2001)	
	C58	KOCHER, et al. Identification and Intracellular Location of MAGE-3 Gene Product. Cancer Res. 55: 2236-2239 (1995)	
	C59	KUNDIG, et al. Fibroblasts as Efficient Antigen-Presenting Cells in Lymphoid Organs. Science, 268: 1343-1347 (1995)	
	C60	KURZROCK, et al. Pilot Study of Low-Dose Interleukin-11 in Patients With Bone Marrow Failure. 19(21): 4165-4172 (2001)	
	C61	LE BON, et al. Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo. Immunity, 14: 461-470 (2001)	
	C62	LEITNER, et al. Enhancement of Tumor-Specific Immune Response with Plasmid DNA Replicon Vectors. Cancer Res. 60: 51-55 (2000)	
	C63	LINDSEY, et al. Impact of the Number of Treatment Courses on the Clinical Response of Patients Who Receive High-Dose Bolus Interleukin-2. J. Clin. Oncol. 18(9): 1954-1959 (2000)	
	C64	LIU, et al. Gene-Based Vaccines. Mol. Ther. 1(6): 497-500 (2000)	
	C65	LUDWIG, et al. Should Alpha-Interferon be Included as Standard Treatment in Multiple Melanoma? Eur. J. Cancer, 34: 12-24 (1998)	
	C66	MAEURER, et al. New Treatment Options for Patients with Melanoma: Review of Melanoma-Derived T-Cell Epitope-Based Peptide Vaccines. Melanoma Res. 6: 11-24 (1996)	
	C67	MARRACK, et al. Type I Interferons Keep Activated T Cells Alive. J. Exp. Med. 189: 521-530 (1999)	
	C68	MARCHAND, et al. Tumor Regressions Observed in Patients with Metastatic Melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1. Int. J. Cancer. 80: 219-230 (1999)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/690,199
				Filing Date	2003-10-21
				First Named Inventor	Astasturov, et al.
				Art Unit	1632
				Examiner Name	Wu Cheng Winston Shen
Sheet	9	of	12	Attorney Docket No: API-02-13-US	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C69	MARSHALL, et al. Phase I Study in Advanced Cancer Patients of a Diversified Prime-And-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti-Carcinoembryonic Antigen Immune Responses. J. Clin. Oncol. 18, 3964-3973 (2000)	
	C70	MARSHALL, J. Carcinoembryonic Antigen-Based Vaccines. Semin. Oncol. (suppl. 8): 30-36 (2003)	
	C71	MATEO, et al. An HLA-A2 Polypeptide Vaccine for Melanoma Immunotherapy. J. Immunol. 163(7): 4058-4063 (1999)	
	C72	MILLER, et al. Targeted Vectors for Gene Therapy. FASEB J. 9: 190-199 (1995)	
	C73	MOINGEON, et al. Cancer Vaccines. 19: 1305-1326 (2001)	
	C74	NAGAO, et al. Oral-Mucosal Administration of Interferon-Alpha Potentiates Immune Response in Mice. J. Int. Cyt. Res. 18(9): 661-666 (1998)	
	C75	NESTLE, et al. Vaccination of Melanoma Patients with Peptide- or Tumor Lysate-Pulsed Dendritic Cells. Nature Med. Vol. 4, No. 3, pp. 328-332 (1998)	
	C76	OERTLI, et al. Rapid Induction of Specific Cytotoxic T Lymphocytes Against Melanoma-Associated Antigens by a Recombinant Vaccinia Virus Vector Expressing Multiple Immunodominant Epitopes and Costimulatory Molecules In Vivo. Human Gene Therapy, 13(4): 569-575 (March 2002)	
	C77	PARDOLL, D.M. Cancer vaccines. Nat. Med. 4: 525-531 (1998)	
	C78	PARKHURST, et al. Improved Induction of Melanoma-Reactive CTL with Peptides from Melanoma Antigen gp100 Modified at HLA-A0201-Binding Residues. J. Immunol. Vol. 157, no. 6, pp. 2539-48 (1996)	
	C79	PARMIANI, et al. Cancer Immunotherapy with Peptide-Based Vaccines: What Have We Achieved? Where Are We Going? J. Natl. Cancer Inst. 94: 805-818 (2002)	
	C80	PATARD, et al. Expression of MAGE Genes in Transitional Cell Carcinomas of the Urinary Bladder. Int. J. Cancer 64: 60-64 (1995)	
	C81	PHAN, et al. Factors Associated with Response to High-Dose Interleukin-2 in Patients with Metastatic Melanoma. J. Clin. Oncol. 19(15): 3477-3482 (2001)	
	C82	PHAN, et al. Cancer Regression and Autoimmunity Induced by Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma. PNAS USA, 100(14): 8372-8377 (2003)	
	C83	QUENTIN, et al. Adenovirus as an Expression Vector in Muscle Cells <i>in vivo</i> . PNAS USA, 89: 2581-2584 (1992)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/690,199
				Filing Date	2003-10-21
				First Named Inventor	Astasturov, et al.
				Art Unit	1632
				Examiner Name	Wu Cheng Winston Shen
Sheet	10	of	12	Attorney Docket No: API-02-13-US	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C84	RAO, et al. Partial Characterization of Two Subpopulations of T4 Cells Induced by Active Specific Intralymphatic Immunotherapy (ASILI) in Melanoma Patients. Vol. 27, abstract 1290, p. 325 (1986)	
	C85	RESTIFO, et al. Antigen Processing In Vivo and the Elicitation of Primary CTL Responses. J. Immunol. 154: 4414-4422 (1995)	
	C86	ROSENBERG, et al. Immunologic and Therapeutic Evaluation of a Synthetic Peptide Vaccine for the Treatment of Patients with Metastatic Melanoma. <i>Nature Med.</i> 4: 321-327 (1998)	
	C87	ROSENBERG, S.A. Progress in Human Tumour Immunology and Immunotherapy. <i>Nature</i> 411, 380-384 (2001)	
	C88	ROSSI, et al. Hyperthermic Isolated Limb Perfusion with Low-Dose Tumor Necrosis Factor- α and Melphalan for Bulky In-Transit Melanoma Metastases. <i>Ann. Surg. Oncol.</i> 11(2): 173-177 (2004)	
	C89	SALGALLER, et al. Immunization Against Epitopes in the Human Melanoma Antigen gp100 Following Patient Immunization with Synthetic Peptides. <i>Cancer Res.</i> Vol. 56, pp. 4749-4757 (1996)	
	C90	SANTINI, et al. Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity In vitro and in Hu-PBL-SCID Mice. <i>J. Exp. Med.</i> 191(10): 1777-1788 (2000)	
	C91	SCHULTZ, et al. A MAGE-3 Peptide Recognized on HLA-B35 and HLA-A1 by Cytolytic T Lymphocytes. <i>Tissue Antigens.</i> 57: 103-109 (2001)	
	C92	SPAGNOLI, et al. Cytotoxic T-cell Induction in Metastatic Melanoma Patients Undergoing Recombinant Vaccinia Virus-Based Immuno-Gene Therapy. <i>Recent Results in Cancer Research.</i> 160: 195-201 (2002)	
	C93	TAKAHASHI, et al. Identification of MAGE-1 and MAGE-4 Proteins in Spermatogonia and Primary Spermatocytes of Testis. <i>Cancer Res.</i> 55: 3478-3482 (1995)	
	C94	TANZARELLA, et al. Identification of a Promiscuous T-Cell Epitope Encoded by Multiple Members of the MAGE Family. <i>Cancer Res.</i> 59: 2668-2674 (1999)	
	C95	TARTAGLIA, et al. NYVAC: A Highly Attenuated Strain of Vaccinia Virus. <i>Virology</i> 188: 217-232 (1992)	
	C96	TARTAGLIA, et al. Protection of Cats Against Feline Leukemia Virus by Vaccination with a Canarypox Virus Recombinant, ALVAC-FL. <i>J. Virol.</i> 67: 2370-2375 (1993)	
	C97	TARTAGLIA, et al. Therapeutic Vaccines Against Melanoma and Colorectal Cancer. <i>Vaccine</i> , 19(17-19): 2571-2575 (2001)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/690,199
				Filing Date	2003-10-21
				First Named Inventor	Astasturov, et al.
				Art Unit	1632
				Examiner Name	Wu Cheng Winston Shen
Sheet	11	of	12	Attorney Docket No: API-02-13-US	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C98	THOMSON, et al. Minimal Epitopes Expressed in a Recombinant Polyepitope Protein are Processed and Presented To CD8+ Cytotoxic T Cells: Implications for Vaccine Design. PNAS USA, 92: 5845-5849 (1995)	
	C99	THOMSON, et al. Recombinant Polyepitope Vaccines for the Delivery of Multiple CD8 Cytotoxic T Cell Epitopes. J. Immunol. 157: 822-826 (1996)	
	C100	THOMSON, et al. Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination. J. Immunol. 160: 1717-1723 (1998)	
	C101	TOES, et al. Protective Anti-Tumor Immunity Induced by Vaccination with Recombinant Adenoviruses Encoding Multiple Tumor-Associated Cytotoxic T Lymphocyte Epitopes in a String-of-Beads Fashion. PNAS USA 94: 14660-14665 (1997)	
	C102	TOSO, et al. MAGE-1-Specific Precursor Cytotoxic T-Lymphocytes Present Among Tumor-Infiltrating Lymphocytes from a Patient with Breast Cancer: Characterization and Antigen-specific Activation. Cancer Res. 56: 16-20 (1996)	
	C103	TOUGH, et al. Induction of Bystander T Cell Proliferation by Viruses and Type I Interferon In Vivo. Science, 272: 1947-1950 (1996)	
	C104	TRAVERSARI, et al. A Nonapeptide Encoded by Human Gene MAGE-1 is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed Against Tumor Antigen MZ2-E. J. Exp. Med. 176: 1453-1457 (1992)	
	C105	TSAO, et al. Hypopigmentation Associated with an Adenovirus-Mediated gp100/MART-1-Transduced Dendritic Cell Vaccine for Metastatic Melanoma. Arch. Dermatol. 138: 799-802 (2002)	
	C106	TUTING, et al. Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses in vitro: Enhancement by Cotransfection of Genes Encoding the TH1 Biasing Cytokines IL-12 and IFN-alpha. J. Immunol. 160: 1139-1147 (1998)	
	C107	VAN BAREN, et al. Tumoral and Immunologic Response After Vaccination with an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells. J. Clin. Oncol. 23(35): 9008-9021 (2005)	
	C108	VAN DEN EYNDE, et al. New Tumor Antigens Recognized by T Cells. Curr. Opin. Immunol. 7: 674-681 (1995)	
	C109	VAN DEN EYNDE, et al. A New Family of Genes Coding for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on a Human Melanoma. J. Exp. Med. 182: 689-698 (1995)	
	C110	VAN DEN EYNDE, et al. T Cell Defined Tumor Antigens. Curr. Opin. Immunol. 9: 684-693 (1997)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/690,199
				Filing Date	2003-10-21
				First Named Inventor	Astasturov, et al.
				Art Unit	1632
				Examiner Name	Wu Cheng Winston Shen
Sheet	12	of	12	Attorney Docket No: API-02-13-US	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C111	VAN DEN EYNDE, et al. Tumor Antigens Recognized by T Lymphocytes. Int. J. Clin. Lab. Res. 27: 81-86 (1997)	
	C112	VAN DER BRUGGEN, et al. A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma. Science, 254: 1643-1647 (1991)	
	C113	VAN DER BRUGGEN, et al. Autologous Cytolytic T Lymphocytes Recognize a MAGE-1 Nonapeptide on Melanomas Expressing HLA-Cw* 1601. Eur. J. Immunol. 24: 2134-2140 (1994)	
	C114	VAN DER BRUGGEN, et al. A Peptide Encoded by Human Gene MAGE-3 and Presented by HLA-A2 Induces Cytolytic T Lymphocytes That Recognize Tumor Cells Expressing MAGE-3. Eur. J. Immunol. 24: 3038-3043 (1994)	
	C115	VAN DER BURG, et al. Induction of p53-Specific Immune Responses in Colorectal Cancer Patients Receiving a Recombinant ALVAC-p53 Candidate Vaccine. Clin. Cancer Res. 8: 1019-1027 (2002)	
	C116	VELDERS, et al. Defined Flanking Spacers and Enhanced Proteolysis is Essential for Eradication of Established Tumors by an Epitope String DNA Vaccine. J. Immunol. 166: 5366-5373 (2001)	
	C117	VON MEHREN, et al. Pilot Study of a Dual Gene Recombinant Avipox Vaccine Containing Both Carcinoembryonic Antigen (CEA) and B7.1 Transgenes in Patients with Recurrent CEA-Expressing Adenocarcinomas. Clin. Cancer Res. 6: 2219-2228 (2000)	
	C118	VON MEHREN, et al. The Influence of Granulocyte Macrophage Colony-Stimulating Factor and Prior Chemotherapy on the Immunological Response to a Vaccine (ALVAC-CEA B7.1) in Patients with Metastatic Melanoma. Clin. Cancer Res. 7: 1181-1191 (2001)	
	C119	WANG, et al. Utilization of an Alternative Open Reading Frame of a Normal Gene in Generating a Novel Human Cancer Antigen. J. Exp. Med. 186:1131-1140 (1996)	
	C120	WEYNANTS, et al. Expression of MAGE Genes by Non-Small-Cell Lung Carcinomas. Int. J. Cancer 59:826-829 (1994)	
	C121	WOLFEL, et al. Two Tyrosine Nonapeptides Recognized on HLA-A2 Melanomas by Autologous Cytolytic T Lymphocytes. Eur. J. Immunol. Vol. 24, pp. 759-764 (1994)	
	C122	XIANG, et al. An Autologous Oral DNA Vaccine Protects Against Murine Melanoma. Proc. Natl. Acad. Sci. USA, vol. 97, no. 10, pp. 5492-5497 (2000)	
	C123	YANG, et al. Randomized Comparison of High-Dose and Low-Dose Intravenous Interleukin- 2 for the Therapy of Metastatic Renal Cell Carcinoma: an Interim Report. J. Clin. Oncol., 12: 1572-1576 (1994)	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached